CALA Calithera Biosciences Inc

Price (delayed)

$2.27

Market cap

$168.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.11

Enterprise value

$78.13M

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven ...

Highlights
Calithera Biosciences's debt has plunged by 59% YoY and by 13% from the previous quarter
CALA's EPS is up by 22% year-on-year and by 8% since the previous quarter
Calithera Biosciences's equity has decreased by 42% YoY and by 12% from the previous quarter
The quick ratio has contracted by 24% YoY

Key stats

What are the main financial stats of CALA
Market
Shares outstanding
74.11M
Market cap
$168.24M
Enterprise value
$78.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.02
Price to sales (P/S)
56.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.04
Earnings
Revenue
$3M
EBIT
-$80.01M
EBITDA
-$78.31M
Free cash flow
-$72.47M
Per share
EPS
-$1.11
Free cash flow per share
-$0.98
Book value per share
$1.12
Revenue per share
$0.04
TBVPS
$1.32
Balance sheet
Total assets
$97.86M
Total liabilities
$14.85M
Debt
$2.37M
Equity
$83.01M
Working capital
$81.52M
Liquidity
Debt to equity
0.03
Current ratio
7.53
Quick ratio
7.41
Net debt/EBITDA
1.15
Margins
EBITDA margin
-2,610.5%
Gross margin
100%
Net margin
-2,666.9%
Operating margin
-2,687.9%
Efficiency
Return on assets
-66.4%
Return on equity
-79.6%
Return on invested capital
-3,253.6%
Return on capital employed
-93.7%
Return on sales
-2,666.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CALA stock price

How has the Calithera Biosciences stock price performed over time
Intraday
10.73%
1 week
3.65%
1 month
2.71%
1 year
-38.15%
YTD
-53.77%
QTD
8.61%

Financial performance

How have Calithera Biosciences's revenue and profit performed over time
Revenue
$3M
Gross profit
$3M
Operating income
-$80.64M
Net income
-$80.01M
Gross margin
100%
Net margin
-2,666.9%
Calithera Biosciences's operating income has increased by 10% YoY and by 7% QoQ
The net income is up by 8% year-on-year and by 7% since the previous quarter

Growth

What is Calithera Biosciences's growth rate over time

Valuation

What is Calithera Biosciences stock price valuation
P/E
N/A
P/B
2.02
P/S
56.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.04
CALA's EPS is up by 22% year-on-year and by 8% since the previous quarter
Calithera Biosciences's equity has decreased by 42% YoY and by 12% from the previous quarter
The P/B is 12% less than the last 4 quarters average of 2.3

Efficiency

How efficient is Calithera Biosciences business performance
CALA's return on equity is down by 22% year-on-year and by 7% since the previous quarter
CALA's ROA is down by 20% year-on-year and by 6% since the previous quarter

Dividends

What is CALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CALA.

Financial health

How did Calithera Biosciences financials performed over time
Calithera Biosciences's total assets has decreased by 41% YoY and by 12% from the previous quarter
The total liabilities has declined by 31% year-on-year and by 10% since the previous quarter
Calithera Biosciences's debt is 97% less than its equity
Calithera Biosciences's debt has plunged by 59% YoY and by 13% from the previous quarter
Calithera Biosciences's equity has decreased by 42% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.